Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.

International journal of clinical oncology - 1 Dec 2011

Kikuchi Hirotoshi, Setoguchi Tomohiko, Miyazaki Shinichiro, Yamamoto Masayoshi, Ohta Manabu, Kamiya Kinji, Sakaguchi Takanori, Konno Hiroyuki

Abstract excerpt

Imatinib mesylate is an effective treatment for recurrent or metastatic gastrointestinal stromal tumors (GISTs), but secondary resistance has been reported. The tyrosine kinase inhibitor sunitinib malate has shown efficacy in imatinib-resistant GISTs, and has been used as second-line therapy for recurrent or metastatic GISTs. However, it is often difficult to treat patients with imatinib- and sunitinib-resistant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Gastrointestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Hepatectomy

Share to Imatinib Mesylate

Share to Piperazines

Share to Pyrroles

Share to Sunitinib

Source

Identifiers

PMID: 21394667
DOI: 10.1007/s10147-011-0208-4

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.PMID 21394667Read ↗

Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.Semantic proximity Read ↗

Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study.Semantic proximity Read ↗

KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.Semantic proximity Read ↗

Primary gastrointestinal stromal tumor of the liver treated with sequential therapy.Semantic proximity Read ↗

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.Semantic proximity Read ↗

Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.Semantic proximity Read ↗

Perioperative treatment of gastrointestinal stromal tumors.Semantic proximity Read ↗

New paradigms in gastrointestinal stromal tumour management.Semantic proximity Read ↗

Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment.Semantic proximity Read ↗

Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).Semantic proximity Read ↗

Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.